Preparation and in vitro–in vivo characterization of trans-resveratrol nanosuspensions
Source abstract
Abstract
Nanosuspensions technique is an important tool to enhance the saturation solubility and dissolution velocity of poorly soluble drugs. Trans-resveratrol (t-Res) with extensive pharmacological effects was severely restricted by poor solubility and short biological half-life. In this study, anti-solvent precipitation was employed to development trans-resveratrol nanosuspensions (t-Res NS) with PVPK30 as stabilizer. The physicochemical properties, in vitro release and in vivo pharmacokinetics of t-Res NS were investigated. The mean particle size, zeta potential, encapsulation efficiency and drug loading of t-Res NS prepared by the optimal prescription were 96.9 nm, -20.4mV, 78% and 28.1%, respectively. The morphology of t-Res nanoparticles was spherical indicated by SEM with amorphous phase verified by XRD and DSC. The t-Res NS present a good physical stability as well as enhanced chemical stability. Compared to crude drug, the in vitro dissolution rate of t-Res NS was increased with fitting Higuchi equation (Q=0.3215t1/2+0.0070). The in vivo pharmacokinetic test in rats showed that the AUC0∼t of t-Res NS (559.4 μg/mL·min) was about 3.6-fold higher than that of t-Res solution. Meanwhile, the MRT of t-Res nanosuspensions was longer than that of t-Res solution. These results suggested that NS may be a potentially nanocarrier for clinical delivery of t-Res.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Toxin Mechanisms and Immunotoxins · Drug Solubulity and Delivery Systems · Sirtuins and Resveratrol in Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Anhui University of Chinese Medicine, Anhui Academy of Chinese Medicine, Hefei 230038, P.R. China
References (39)
Show source-provided references
1. Stress induced phenylpropanoid metabolism10.2307/3870059 ↗
2. Resveratrol and its antioxidant and antimicrobial effectiveness10.1016/S0308-8146(03)00157-2 ↗
3. Resveratrol inhibits Staphylococcus aureus-induced TLR2/MyD88/NF-κB-dependent VCAM-1 expression in human lung epithelial cells10.1042/CS20130816 ↗
4. Anti-inflammatory effects of resveratrol and oligostilbenes from Vitis thunbergii var. taiwaniana against lipopolysaccharide-induced arthritis10.1021/jf104718g ↗
5. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels10.1016/j.colsurfb.2009.03.010 ↗
6. How does SIRT1 affect metabolism, senescence and cancer?10.1038/nrc2562 ↗
7. Resveratrol in metabolic health: An overview of the current evidence and perspectives10.1111/nyas.12141 ↗
8. Resveratrol and cardiovascular health10.1016/j.mam.2010.09.001 ↗
9. A human t-RNA synthetase is a potent PARP1-activating effector target for resveratrol10.1038/nature14028 ↗
10. Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest10.1002/jcb.24134 ↗
11. Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro10.18632/oncotarget.2632 ↗
12. M.L. Wu, H. Li, L.J. Yu, X.Y. Chen, Q.Y. Kong, X. Song, X.H. Shu and J. Liu, Short-term resveratrol exposure causes in vitro and, vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One 9(2) (2014), e89806.10.1371/journal.pone.0089806 ↗
13. Administration of resveratrol: What formulation solutions to bioavailability limitations10.1016/j.jconrel.2011.09.083 ↗
14. Transport stability, and biological activity of resveratrol10.1111/j.1749-6632.2010.05871.x ↗
15. Resveratrol upregulates Nrf2 expression to attenuate methylglyoxal-induced insulin resistance in HepG2 cells10.1021/jf302831d ↗
16. Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC–MS/MS and their pharmacokinetics in dogs10.1016/j.jpba.2011.10.023 ↗
17. Resveratrol encapsulated in novel fusogenic liposomes activates Nrf2 and attenuates oxidative stress in cerebromicrovascular endothelial cells from aged rats10.1093/gerona/glu029 ↗
18. Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential10.1517/17425247.2014.890588 ↗
19. Trans-resveratrol self-nano-emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: Optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies10.3109/10717544.2014.885616 ↗
20. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress10.1016/j.ijpharm.2009.03.021 ↗
21. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions10.1016/j.ijpharm.2009.07.005 ↗
22. In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size10.1016/j.colsurfb.2012.09.006 ↗
23. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products10.1016/j.ijpharm.2008.07.023 ↗
24. Properties and bioaccessibility of arsenic sulphide nanosuspensions10.1016/j.matlet.2013.04.003 ↗
25. In vitro–in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps10.1016/j.ijpharm.2013.04.060 ↗
26. Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies10.1016/j.colsurfb.2013.06.004 ↗
27. A mini review of nanosuspensions development10.3109/1061186X.2011.645161 ↗
28. Diclofenac nanosuspensions: Influence of preparation procedure and crystal form on drug dissolution behavior10.1016/j.ijpharm.2009.01.024 ↗
29. Drug nanocrystals in the commercial pharmaceutical development process10.1016/j.ijpharm.2012.09.034 ↗
30. Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement10.1016/j.ejps.2012.12.026 ↗
31. Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo10.1016/j.ijpharm.2013.07.058 ↗
32. Nanocrystal preparation: Low-energy precipitation method revisited10.1021/cg4000473 ↗
33. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability10.1208/s12249-011-9750-7 ↗
34. Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan10.1208/s12249-012-9860-x ↗
35. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability10.1016/j.ejps.2010.04.006 ↗
36. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery10.3109/02652048.2011.642015 ↗
37. Sonication-assisted synthesis of polyelectrolyte-coated curcumin nanoparticles10.1021/la101246a ↗
38. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage-impact of different polymers10.1002/jps.23358 ↗
39. Nucleation and crystal growth in supersaturated solutions of a model drug10.1016/j.jcis.2008.05.034 ↗